Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.

Publication date: Jul 08, 2020

Data on serial liver biochemistries of patients infected by different human coronaviruses (HCoVs) are lacking. The impact of liver injury on adverse clinical outcomes in coronavirus disease 2019 (COVID-19) patients remains unclear.

This was a retrospective cohort study using data from a territory-wide database in Hong Kong. COVID-19, severe acute respiratory syndrome (SARS) and other HCoV patients were identified by diagnosis codes and/or virological results. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation was defined as ALT/AST ?2 x upper limit of normal (ie, 80 U/L). The primary end point was a composite of intensive care unit (ICU) admission, use of invasive mechanical ventilation and/or death.

We identified 1040 COVID-19 patients (mean age 38 years, 54% men), 1670 SARS patients (mean age 44 years, 44% men) and 675 other HCoV patients (mean age 20 years, 57% men). ALT/AST elevation occurred in 50.3% SARS patients, 22.5% COVID-19 patients and 36.0% other HCoV patients. For COVID-19 patients, 53 (5.1%) were admitted to ICU, 22 (2.1%) received invasive mechanical ventilation and 4 (0.4%) died. ALT/AST elevation was independently associated with primary end point (adjusted OR (aOR) 7.92, 95% CI 4.14 to 15.14, p

Concepts Keywords
Alanine Aminotransferase Enzymes
ALT Alanine transaminase
Aminotransferase RTT
AOR Glutamate
Aspartate Hepatology
AST Clinical medicine
Cohort Medicine
Coronavirus Medical specialties
Hong Kong Mechanical ventilation
Intensive Care Unit Liver injury
Liver SARS
Mechanical Ventilation Coronavirus
SARS Aspartate transaminase
Hepatitis
Liver function tests

Semantics

Type Source Name
disease MESH severe acute respiratory syndrome
disease MESH diagnosis
drug DRUGBANK L-Alanine
disease MESH death
disease MESH men
disease MESH cholestasis
disease MESH hepatitis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *